PMID- 36537908
OWN - NLM
STAT- MEDLINE
DCOM- 20221222
LR  - 20221222
IS  - 2589-0646 (Electronic)
IS  - 2589-0646 (Linking)
VI  - 15
IP  - 3
DP  - 2022 Dec 15
TI  - Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central 
      Nervous System Involvement.
PG  - 66-72
LID - 10.56875/2589-0646.1024 [doi]
AB  - BACKGROUND AND OBJECTIVE: CAR T-cell therapy has significantly improved the 
      outcomes of patients with relapsed or refractory (R/R) B-cell non-Hodgkin 
      lymphoma (B-NHL). However, most clinical trials excluded patients with central 
      nervous system (CNS) involvement due to uncertain efficacy and safety. MATERIAL 
      AND METHODS: On January 1, 2022, we searched PubMed to identify all published 
      literature associated with current commercial CAR T-cell therapies for B-NHL, 
      including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), 
      brexucabtagene autoleucel (brexu-cel), and lisocabtagene maraleucel (liso-cel). 
      Studies that involved patients with either primary or secondary CNS lymphoma, and 
      evaluated response rate, adverse events (AEs), or survival were included and 
      summarized. RESULT: Herein, we summarize the results of 11 studies qualified for 
      our inclusion criteria, reporting 58 lymphoma patients with CNS Involvement with 
      44 evaluable for clinical response, 25 for immune effector cell-associated 
      neurotoxicity syndrome (ICANS) and 48 for Cytokine release syndrome (CRS). 
      Objective response was achieved in 62% (16/26) of patients, and CR was achieved 
      in 52% (23/44) of patients. Forty-four percent (11/25) developed ICANS, and 35% 
      (17/48) developed severe ICANS (grade>/=3). CRS was reported in 63% (15/24) of 
      patients, while severe CRS (grade>/=3) was reported in 7% (3/42) of patients. 
      CONCLUSION: Based on our PubMed literature review, we conclude that CAR T-cell 
      therapy may benefit patients with CNS lymphoma with promising response rates and 
      acceptable AE. However, definite conclusions cannot be drawn until data with a 
      larger sample size is available.
FAU - Yi, Dongni
AU  - Yi D
AD  - Thomas Jefferson University Sidney Kimmel Medical College, United States.
FAU - Gergis, Mia
AU  - Gergis M
AD  - Tufts University, United States.
FAU - Elgohary, Ghada
AU  - Elgohary G
AD  - Ain Shams University, Egypt.
FAU - Hsu, Jingmei
AU  - Hsu J
AD  - Weill Cornell Medicine, United States.
FAU - Yang, Yang
AU  - Yang Y
AD  - Thomas Jefferson University Sidney Kimmel Medical College, United States.
FAU - Bi, Xia
AU  - Bi X
AD  - Thomas Jefferson University Sidney Kimmel Medical College, United States.
FAU - Gergis, Usama
AU  - Gergis U
AD  - Thomas Jefferson University Sidney Kimmel Medical College, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221215
PL  - Saudi Arabia
TA  - Hematol Oncol Stem Cell Ther
JT  - Hematology/oncology and stem cell therapy
JID - 101468532
RN  - 0 (cell-associated neurotoxicity)
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects
MH  - *Receptors, Chimeric Antigen
MH  - *Lymphoma/therapy
MH  - Cytokine Release Syndrome
MH  - Central Nervous System
MH  - T-Lymphocytes
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy
MH  - Receptors, Antigen, T-Cell
EDAT- 2022/12/21 06:00
MHDA- 2022/12/23 06:00
CRDT- 2022/12/20 10:06
PHST- 2022/05/22 00:00 [received]
PHST- 2022/07/12 00:00 [accepted]
PHST- 2022/12/20 10:06 [entrez]
PHST- 2022/12/21 06:00 [pubmed]
PHST- 2022/12/23 06:00 [medline]
AID - 2589-0646.1024 [pii]
AID - 10.56875/2589-0646.1024 [doi]
PST - epublish
SO  - Hematol Oncol Stem Cell Ther. 2022 Dec 15;15(3):66-72. doi: 
      10.56875/2589-0646.1024.